Trial Profile

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 225 Actinium AZD 2284 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors AstraZeneca

Most Recent Events

27 Mar 2025 Planned End Date changed from 15 May 2029 to 16 Apr 2029.
27 Mar 2025 Status changed from not yet recruiting to recruiting.
26 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com